Here’s a startling fact: Respiratory Syncytial Virus (RSV) sends an estimated 170,000 adults aged 50 and older to the hospital each year in the U.S., claiming 14,000 lives. But here’s where it gets controversial: while most adults experience mild symptoms, RSV can turn deadly for those 75 and older, especially those in long-term care or with chronic conditions. So, what’s the solution? The American College of Physicians (ACP) has just issued a bold recommendation: all adults aged 75 and older should receive a protein subunit RSV vaccine. And this is the part most people miss—adults aged 60 to 74 at higher risk for severe RSV may also consider it.
Published in Annals of Internal Medicine, the ACP’s updated practice points (https://www.acpjournals.org/doi/10.7326/ANNALS-25-05485) highlight the vaccine’s potential to save lives by preventing severe illness and hospitalization. Unlike the annual flu shot, the RSV vaccine is a one-time deal—though researchers are still studying if boosters will be needed.
Here’s the catch: While the benefits for those 75+ are clear, the ACP notes that adults aged 60-74 see fewer advantages, yet face the same potential risks, such as rare cases of Guillain-Barré syndrome. This raises a thought-provoking question: Should the vaccine be more widely recommended, or is it best reserved for the highest-risk groups?
The ACP Population Health and Medical Science Committee (PHMSC) based these recommendations on a rapid review of evidence, weighing the vaccine’s benefits against its harms. For older adults, the scale tips toward protection—but what about everyone else?
RSV isn’t just a cold; it can lead to life-threatening lower respiratory infections, especially in vulnerable populations. Chronic conditions like kidney disease, diabetes, or heart disease amplify the risk. By targeting those most at risk, the ACP aims to reduce hospitalizations and deaths.
But here’s the bigger question: As RSV vaccines become more accessible, should we rethink who gets them? Should age 60 be the cutoff, or should we expand eligibility based on individual health risks? Let’s spark a conversation—what do you think? Share your thoughts in the comments below!
